Appendices

Copy of registration forms used in the MoMaTEC trials;

#4 Inclusion form

#5 Follow-up form

#4 Inclusion form revised after introduction of FIGO 2009 classification

#5 Follow-up form revised after introduction of FIGO 2009 classification
Study of prognostic markers
in endometrial cancer curettage

# 4Registration– clinical data at primary treatment

Parity (no. of births): Patients date of birth month year
Menopausal status: pre- (1) peri- (2) postmenopausal (3)

Primary treatment date for primary surgery:
- hyst. with salpingoophorectomi (1)
- palliative tumour reduction (2)
- curettage only (3)

Lymphadenectomy: yes (1) no (2) no. of lymph nodes removed

Additional treatment as a part of primary treatment:
- no (0)
- external radiation (1)
- internal radiation (2)
- chemotherapy (3)
- hormonal treatment (4)
- chemotherapy + radiation (5)
- other (9)

Supplementary information:________________________________________

Surgical FIGO stage (1988 criterias including histopathologic evaluation):
- FIGO I (10)
- FIGO IIA (21)
- FIGO III (30)
- FIGO IV (40)
- FIGO IA (11)
- FIGO IIB (22)
- FIGO IIIA (31)
- FIGO IIIB (32)
- FIGO IVA (41)
- FIGO IIC (33)
- FIGO IB (12)
- FIGO II (20)
- FIGO IIIB (32)
- FIGO IVB (42)
- FIGO IC (13)
- FIGO IIC (33)
- FIGO IVB (42)

Histopathologic results:
Histologic subtype:
- endometrioid (1)
- adenosq. (2)
- clear cell (3)
- serous pap. (4)
- other (6)
- hyperplasia (5)

Histologic grade:
- high (grade 1, well differentiated) (1)
- medium (grade 2) (2)
- low (grade 3, poorly diff.) (3)

Lymph node metastases, histologically verified:
- yes (1)
- no (2)
Number of positive lymph nodes

________________________________________  ___________  ____________________________
Place, date  Signature physician  Name physician in print

Contact info: Professor Helga B Salvesen, e-post: helga.salvesen@uib.no
Avdelingsingeniør Britt Edvardsen, e-post: britt.edvardsen@helse-bergen.no
Adresse: Kvinneklinikken 5021 Bergen 55974200 55974968
Haukeland Universitetssykehus Norge
# 5 Registration– clinical follow-up

**Recurrence:**
- Yes (1) no (2)

Date of recurrence:

Location of recurrence: pelvic (1) distant metastases (2), where?

**Treatment of recurrence**
- No (0)
- External radiation (1)
- Internal radiation (2)
- Chemotherapy (3)
- Hormonal treatment (4)
- Chemotherapy + radiation (5)
- Other (9)

Additional information:

**Status at last follow-up:**

Date for last follow-up information:

- Alive and well (1)
- Alive with active disease (2)
- Dead from other causes (3)
- Dead with but not due to active disease (4)
- Dead from disease (5)

Place, date  Signature physician  Name physician in print

Contact info: Professor Helga B Salvesen, e-post: helga.salvesen@uib.no
Avdelingsingeniør Britt Edvardsen, e-post: britt.edvardsen@helse-bergen.no
Adresse: Kvinneklinikken 5021 Bergen 55974200 55974968
Haukeland Universitetssykehus Norge
# 4 Registration – clinical data at primary treatment

Parity (no. of births): Patient’s date of birth month year

Menopausal status: pre- (1) peri- (2) postmenopausal (3)

**Curettings histology:** low risk (1)* high risk (2)**

*low risk: benign, hyperplasia, endometrioid grade 1-2.  
**High risk: serous-papillary, clear cell, carcinocarcoma, endometrioid grade 3, undifferentiated

**Primary treatment** date of primary surgery:

hyst. with salpingoophorectomi (1) palliative tumour reduction (2) curettage only (3)

Lymphadenectomy: pelvic (1) paraaortic (2) not performed (3) no.nodes removed

**Additional treatment as a part of primary treatment:**

none (0) external radiation (+/- internal) (1) internal radiation (2) chemotherapy (3)

hormonal treatment (4) chemotherapy + radiation (5) other (9)

Supplementary information/ type of chemotherapy: ____________________________

**Surgical FIGO stage (2009 criteria including histopathlogic evaluation):**

<table>
<thead>
<tr>
<th>FIGO I (10)</th>
<th>FIGO IA (11)</th>
<th>FIGO IB (12)</th>
<th>FIGO IC (13)</th>
<th>FIGO II (20)</th>
</tr>
</thead>
<tbody>
<tr>
<td>FIGO III (30)</td>
<td>FIGO IIIA (31)</td>
<td>FIGO IIIB (32)</td>
<td>FIGO IIIC1 (33)</td>
<td>FIGO IIIC2 (34)</td>
</tr>
<tr>
<td>FIGO IV (40)</td>
<td>FIGO IVA (41)</td>
<td>FIGO IVB (42)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Histopathologic results:**

**Depth of myometrial infiltration:** <50% (1) >50% (2)

**Histologic subtype:** endometrioid (1) adenosq. (2) clear cell (3) serous pap. (4)

carcinosarcoma (6) hyperplasia (5) undifferentiated/other (7)

**Histologic grade:** grade 1, well differentiated (1) grade 2 (2) grade 3, poorly diff. (3)

**Lymph node metastases histologically verified:** yes (1) no (2) not applicable (0)

**Number of positive lymph nodes**

<table>
<thead>
<tr>
<th>Place, date</th>
<th>Signature physician</th>
<th>Name physician in print</th>
</tr>
</thead>
</table>

**Kontaktpersoner:** Professor Helga B. Salvesen, e-post: helga.salvesen@uib.no  
Aveldingsingeniør Brit Edvardsen, e-post: britt.edvardsen@helse-bergen.no

**Adresse:** Kvinneklinikken 5021 Bergen | Telefon: 55974200 | Teledfax: 55974968

Klinikk Haukeland Universitetssykehus Norge
# 5  *Registration– clinical follow-up*

<table>
<thead>
<tr>
<th>Recurrence:</th>
<th>yes (1)</th>
<th>no (2)</th>
<th>progression/ non radically operated (3)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Date of recurrence/progression:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Localisation:</td>
<td>vaginal vault (3)</td>
<td>other pelvic (4)</td>
<td>distant metastases (2)</td>
</tr>
<tr>
<td>If distant; where?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Confirmation by histology:</td>
<td>yes (1)</td>
<td>no (2)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Treatment of recurrence/ progression:</th>
<th>None (0)</th>
<th>external radiation (+/- internal) (1)</th>
<th>internal radiation (2)</th>
<th>chemotherapy (3)</th>
<th>Hormonal treatment (4)</th>
<th>chemotherapy + radiation (5)</th>
<th>other (9)</th>
</tr>
</thead>
</table>

Additional information/type of chemotherapy:

_______________________________________________________________________________

<table>
<thead>
<tr>
<th>Status at latest follow-up:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Date of latest follow-up:</td>
</tr>
<tr>
<td>alive, without recurrence of endometrial cancer (1)</td>
</tr>
<tr>
<td>alive, with known recurrence of endometrial cancer (2)</td>
</tr>
<tr>
<td>dead from other causes than endometrial cancer (3)</td>
</tr>
<tr>
<td>dead with, but not due to, endometrial cancer (4)</td>
</tr>
<tr>
<td>dead from endometrial cancer (5)</td>
</tr>
</tbody>
</table>

Place, date  Signature physician  Name physician in print